This interaction between CHAC1 and Notch3 offers potential therapeutic insights, suggesting that targeting CHAC1 could amplify TMZ’s efficacy against glioblastoma by mitigating Notch3 activity (Chen P.-H. The gene discussed is CHAC1; the disease is glioblastoma.